Restoration of Noradrenergic Function in Parkinson's Disease Model Mice

被引:10
|
作者
Cui, Kui [1 ]
Yang, Fan [1 ,2 ]
Tufan, Turan [1 ]
Raza, Muhammad U. [1 ]
Zhan, Yanqiang [1 ,3 ]
Fan, Yan [1 ,4 ]
Zeng, Fei [1 ,3 ]
Brown, Russell W. [1 ]
Price, Jennifer B. [5 ]
Jones, Thomas C. [5 ]
Miller, Gary W. [6 ]
Zhu, Meng-Yang [1 ,7 ]
机构
[1] East Tennessee State Univ, Quillen Coll Med, Dept Biomed Sci, Johnson City, TN 37604 USA
[2] Asia Metropolitan Univ, Hong Kong Inst, Hong Kong, Peoples R China
[3] Wuhan Univ, Dept Neurol, Renmin Hosp, Wuhan, Peoples R China
[4] Nantong Univ, Dept Biochem, Coll Med, Nantong, Peoples R China
[5] East Tennessee State Univ, Dept Biol Sci, Coll Arts & Sci, Johnson City, TN 37604 USA
[6] Columbia Univ, Mailmen Sch Publ Hlth, Dept Environm Hlth Sci, New York, NY USA
[7] Harvard Med Sch, Karp Family Res Labs, Dept Surg, Boston Childrens Hosp, Boston, MA 02115 USA
来源
ASN NEURO | 2021年 / 13卷
关键词
locus coeruleus; norepinephrine; tyrosine hydroxylase; dopamine; dopamine β -hydroxylase; Morris water maze; DOPAMINE-BETA-HYDROXYLASE; NEUROTROPHIC FACTOR EXPRESSION; REDUCED VESICULAR STORAGE; MORRIS WATER MAZE; NIGRAL CELL LOSS; LOCUS-COERULEUS; TRANSCRIPTION FACTOR; NOREPINEPHRINE TRANSPORTER; GENE-THERAPY; MOUSE MODEL;
D O I
10.1177/17590914211009730
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Dysfunction of the central noradrenergic and dopaminergic systems is the primary neurobiological characteristic of Parkinson's disease (PD). Importantly, neuronal loss in the locus coeruleus (LC) that occurs in early stages of PD may accelerate progressive loss of dopaminergic neurons. Therefore, restoring the activity and function of the deficient noradrenergic system may be an important therapeutic strategy for early PD. In the present study, the lentiviral constructions of transcription factors Phox2a/2b, Hand2 and Gata3, either alone or in combination, were microinjected into the LC region of the PD model VMAT2 Lo mice at 12 and 18 month age. Biochemical analysis showed that microinjection of lentiviral expression cassettes into the LC significantly increased mRNA levels of Phox2a, and Phox2b, which were accompanied by parallel increases of mRNA and proteins of dopamine beta-hydroxylase (DBH) and tyrosine hydroxylase (TH) in the LC. Furthermore, there was considerable enhancement of DBH protein levels in the frontal cortex and hippocampus, as well as enhanced TH protein levels in the striatum and substantia nigra. Moreover, these manipulations profoundly increased norepinephrine and dopamine concentrations in the striatum, which was followed by a remarkable improvement of the spatial memory and locomotor behavior. These results reveal that over-expression of these transcription factors in the LC improves noradrenergic and dopaminergic activities and functions in this rodent model of PD. It provides the necessary groundwork for the development of gene therapies of PD, and expands our understanding of the link between the LC-norepinephrine and dopamine systems during the progression of PD.
引用
收藏
页数:18
相关论文
共 50 条
  • [1] Restoration of intestinal function in an MPTP model of Parkinson’s Disease
    L. J. Ellett
    L. W. Hung
    R. Munckton
    N. A. Sherratt
    J. Culvenor
    A. Grubman
    J. B. Furness
    A. R. White
    D. I. Finkelstein
    K. J. Barnham
    V. A. Lawson
    Scientific Reports, 6
  • [2] Restoration of intestinal function in an MPTP model of Parkinson's Disease
    Ellett, L. J.
    Hung, L. W.
    Munckton, R.
    Sherratt, N. A.
    Culvenor, J.
    Grubman, A.
    Furness, J. B.
    White, A. R.
    Finkelstein, D. I.
    Barnham, K. J.
    Lawson, V. A.
    SCIENTIFIC REPORTS, 2016, 6
  • [3] Preserved noradrenergic function in Parkinson's disease patients with rest tremor
    Kinnerup, Martin B.
    Sommerauer, Michael
    Damholdt, Malene F.
    Schaldemose, Jeppe L.
    Ismail, Rola
    Terkelsen, Astrid J.
    Staer, Kristian
    Hansen, Allan
    Fedorova, Tatyana D.
    Knudsen, Karoline
    Skjaerbaek, Casper
    Borghammer, Per
    Pavese, Nicola
    Brooks, David J.
    Nahimi, Adjmal
    NEUROBIOLOGY OF DISEASE, 2021, 152
  • [4] The Noradrenergic System in Parkinson's Disease
    Paredes-Rodriguez, Elena
    Vegas-Suarez, Sergio
    Morera-Herreras, Teresa
    De Deurwaerdere, Philippe
    Miguelez, Cristina
    FRONTIERS IN PHARMACOLOGY, 2020, 11
  • [5] Parkinson's disease and noradrenergic system
    Brefel-Courbon, C
    PRESSE MEDICALE, 2002, 31 (26): : 1240 - 1242
  • [6] Mice with selective loss of noradrenergic neurons as a potential novel model to study presymptomatic phase of Parkinson's disease
    Barut, J.
    Jurga, A.
    Rafa-Zablocka, K.
    Baginska, M.
    Parlato, R.
    Domanskyi, A.
    Nalepa, I.
    Krainer, G.
    FEBS OPEN BIO, 2019, 9 : 231 - 231
  • [7] Noradrenergic modulation of saccades in Parkinson's disease
    Orlando, Isabella F.
    Hezemans, Frank H.
    Ye, Rong
    Murley, Alexander G.
    Holland, Negin
    Regenthal, Ralf
    Barker, Roger A.
    Williams-Gray, Caroline H.
    Passamonti, Luca
    Robbins, Trevor W.
    Rowe, James B.
    O'Callaghan, Claire
    BRAIN COMMUNICATIONS, 2024, 6 (05)
  • [8] Cholinergic and noradrenergic aspects of Parkinson's disease
    Husain, Masud
    BRAIN, 2024, 147 (04) : 1113 - 1114
  • [9] Neuroprotective effect of a-Mangostin in restoration mitochondrial function in MPTP-induced Parkinson's disease in mice
    Prakash, A.
    Majeed, A. B.
    Ramasamy, K.
    Hasan, M.
    MOVEMENT DISORDERS, 2017, 32
  • [10] The functional anatomy of noradrenergic neurons in Parkinson's disease
    Soldani, P
    Fornai, F
    FUNCTIONAL NEUROLOGY, 1999, 14 (02) : 97 - 109